Oruka Therapeutics CEO sells 25,000 shares under plan
The same-day sales were reported under a Rule 10b5-1 plan entered into May 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. Chief Executive Officer Lawrence Otto Klein exercised an employee warrant for 25,000 common shares on November 2, 2026, at $7.80 per share. The warrant entry reports 1,503,513 employee warrants following the transaction. Klein also sold 25,000 common shares that day at reported weighted-average prices ranging from $94.7718 to $98.4033 per share; the sales were made under a Rule 10b5-1 plan entered into May 14, 2026. The warrant expires July 14, 2034.
Insider Trade Summary 10b5-1
Exercise and Sale: 25,000 shares ($2.20M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Klein Lawrence Otto
Role
Chief Executive Officer
Sold
25,000 shs ($2.39M)
Approx. gross sale proceeds
$2.39M
Approx. exercise cost
$195K
Approx. pre-tax spread
$2.20M
Share of Position Sold
2.6%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Warrant (right to buy) F7 | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $7.80 | $195K |
| Sale | Common Stock F1, F2 | 6,466 | $94.7718 | $613K |
| Sale | Common Stock F1, F3 | 15,036 | $95.6363 | $1.44M |
| Sale | Common Stock F1, F4 | 2,442 | $96.7021 | $236K |
| Sale | Common Stock F1, F5 | 756 | $97.4544 | $74K |
| Sale | Common Stock F1, F6 | 300 | $98.4033 | $30K |
Holdings After Transaction:
Employee Warrant (right to buy) — 1,503,513 contracts (Direct);
Common Stock — 923,128 shares (Direct)
Holdings Before and After:
Employee Warrant (right to buy), 1,528,513 to 1,503,513 contracts (Direct);
Common Stock, 923,128 to 923,128 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (7)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.25 to $95.24, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.25 to $96.23, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.25 to $97.24, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.30 to $98.12, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.40 to $98.41, inclusive.
- F7. The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.
Key Figures
Common shares acquired through warrant exercise: 25,000 shares
Warrant exercise price: $7.80 per share
Common shares sold: 25,000 shares
+3 more
6 metrics
Common shares acquired through warrant exercise
25,000 shares
November 2, 2026
Warrant exercise price
$7.80 per share
November 2, 2026
Common shares sold
25,000 shares
November 2, 2026
Reported weighted-average sale prices
$94.7718–$98.4033 per share
Lowest to highest across five sale entries on November 2, 2026
Employee warrants following transaction
1,503,513 warrants
Following the November 2, 2026 transaction
Warrant expiration
July 14, 2034
Employee warrant
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Warrant (right to buy)
3 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Warrant (right to buy) financial
"Employee Warrant (right to buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What vesting schedule was disclosed for Klein's ORKA warrant?
The warrant vests as to 1/4 of the underlying shares on April 3, 2025, and as to 1/48 of the underlying shares monthly from April 3, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
